In Vitro and In Vivo Pharmacology for Glioma Drug Discovery
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 1101
Special Issue Editor
Interests: glioma; complementary therapy in glioma; glioma metabolism; remodeling of glioma metabolism; immunotherapy in glioma
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gliomas are a diverse group of brain tumors originating from glial cells. The aggressive nature of glioma, high mortality, and number of complications are still a serious problem in neuro-oncology. Standard treatments of glioma include surgical resection, chemotherapy with temozolomide (TEMO), radiotherapy, and new therapeutic strategies that seemed to be promising neither prolonged patients’ lives, nor did they reduce cancer recurrence rates. Therefore, there is a great effort to propose new therapeutic lines or to design new drugs for glioma therapy. Preclinical cancer models are valuable tools in oncology studies, including glioma, to recapitulate tumor microenvironments and host immune responses.
Therefore, we are pleased to invite you to the Special Issue “In Vitro and In Vivo Pharmacology for Glioma Drug Discovery’’. The aim and scope of the Special Issue is to search for new strategies and drugs using modern in vitro and in vivo systems. In this Special Issue, original research articles and reviews are welcome.
Dr. Anna Bielecka-Wajdman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pre-clinical modern in vitro /in vivo glioma models
- complementary glioma therapy
- immunotherapy in glioma
- inhibition of glioma recurrence
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
